Roche sees receding biosimilar impact, but Vabysmo slump returns on July 24, 2026 2026 Attitude Biosimilars Demand (clinical) Hemlibra Impact food supplement legacy cancer Ocrevus Roche (company) Sales - occupational activity U.S. United States Vabysmo slump Xolair +